PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617

Journal of Nuclear Medicine

Volumn 57, Issue 8, 2016, Pages 1170-1176

  Kratochwil, Clemens ^a   Giesel, Frederik L ^a,b   Stefanova, Melsa ^a   Benesova, Martina ^b   Bronzel, Marcus ^c   Afshar Oromieh, Ali ^a,b   Mier, Walter ^a   Eder, Matthias ^b   Kopka, Klaus ^b   Haberkorn, Uwe ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ABX CRO   (Germany)

Author keywords

177Lu; Castration resistant prostate cancer; Dosimetry; Pharmacokinetics; PSMA; Radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN 11 GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN 617 LU 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIPEPTIDE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PSMA-617; SINGLE HETEROCYCLIC RINGS; TUMOR MARKER;

ADULT; AGED; ANEMIA; ARTICLE; BETA RADIATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; ISOTOPE LABELING; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION SAFETY; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARD UPTAKE VALUE; THROMBOCYTOPENIA; TREATMENT RESPONSE; XEROSTOMIA; BLOOD; CLINICAL TRIAL; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; DIPEPTIDES; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84980463813     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.171397     Document Type: Article

References (34)

1. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarci-noma: a study of 184 cases. Cancer. 1998;82:2256-2261.
2. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
3. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internal-ization of prostate-specific membrane antigen. Cancer Res. 1998;58:4055-4060.
4. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006;12:2591-2596.
5. Rose JN, Crook JM. The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2015;7:135-145.
6. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
7. 177Lu-Labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46:850-858.
8. 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11:7195s-7200s.
9. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
10. Benesová M, Schäfer M, Bauder-Wüst U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914-920.
11. 177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.
12. Gourni E, Canovas C, Goncalves V, Denat F, Meyer PT, Maecke HR. (R)-NODAGA-PSMA: A versatile precursor for radiometal labeling and nuclear imaging of PSMA-positive tumors. PLoS One. 2015;10:e0145755.
13. Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51:7737-7743.
14. 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013;23:1557-1563.
15. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779-796.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). cancer.gov website. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Published August 9, 2006. Accessed April 14, 2016.
17. Leard SE, Freis ED. Changes in the volume of the plasma, interstitial and intracellular fluid spaces during hydration and dehydration in normal and edematous subjects. Am J Med. 1949;7:647-654.
18. SSK. Notwendigkeit der stationären Durchführung der Ganzkörperszintigraphie mit I-131 beim Schilddrüsenkarzinom. Strahlenschutzkommission website. http://www.ssk.de/SharedDocs/Beratungsergebnisse-PDF/2004/Ganzkoerpers-zintigraphie-I131.html?nn52241514. BAnz Nr. 158. Published April 22, 2004. Accessed April 14, 2016.
19. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
20. 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42-51.
21. 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:1976-1983.
22. Hey J, Setz J, Gerlach R, et al. Parotid gland-recovery after radiotherapy in the head and neck region: 36 months follow-up of a prospective clinical study. Radiat Oncol. 2011;6:125.
23. Cremonesi M, Ferrari M, Di Dia A, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155-167.
24. Kratochwil C, Giesel FL, Leotta K, et al. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med. 2015;56:293-298.
25. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76.
26. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41:2106-2119.
27. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537-1547.
28. Chi K, Hotte SJ, Joshua AM, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol. 2015;26:2044-2056.
29. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3-6.
30. van Soest RJ, van Royen ME, de Morrée ES, et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013;49:3821-3830.
31. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108: 9578-9582.
32. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334.
33. Lee DY, Li KC. Molecular theranostics: a primer for the imaging professional. AJR. 2011;197:318-324.
34. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.